{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:25:29Z","timestamp":1782257129858,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014824","name":"Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.dmd.2025.100161","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:22:44Z","timestamp":1757607764000},"page":"100161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Structural characterization of in vivo and in vitro metabolites of bosutinib by liquid chromatography-tandem mass spectrometry, in combination with the in silico methodologies for toxicity and metabolism prediction"],"prefix":"10.1016","volume":"53","author":[{"given":"Sowmya","family":"Chaganti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Pimpre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Barik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrilekha","family":"Chilvery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3274-4616","authenticated-orcid":false,"given":"Kalpana","family":"Talari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandraiah","family":"Godugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6389-5994","authenticated-orcid":false,"given":"Gananadhamu","family":"Samanthula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.dmd.2025.100161_bib1","doi-asserted-by":"crossref","first-page":"25419","DOI":"10.1074\/jbc.R110.200055","article-title":"Drug metabolite profiling and identification by high-resolution mass spectrometry","volume":"286","author":"Zhu","year":"2011","journal-title":"J Biol Chem"},{"issue":"Suppl 3","key":"10.1016\/j.dmd.2025.100161_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/rcm.8235","article-title":"Mass spectrometry in drug metabolism and pharmacokinetics: current trends and future perspectives","volume":"33","author":"Cuyckens","year":"2019","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"10","key":"10.1016\/j.dmd.2025.100161_bib3","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.ejca.2010.02.032","article-title":"Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia","volume":"46","author":"Boschelli","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.dmd.2025.100161_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40487-015-0010-y","article-title":"Bosutinib for chronic myeloid leukemia","volume":"3","author":"Breccia","year":"2015","journal-title":"Rare Cancers Ther"},{"issue":"10","key":"10.1016\/j.dmd.2025.100161_bib7","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of bosutinib","volume":"55","author":"Abbas","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmd.2025.100161_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-018-0685-2","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100161_bib9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/annonc\/mdy019","article-title":"Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"29","author":"Khoury","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100161_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5849","article-title":"In vivo and in vitro metabolite profiling of nirmatrelvir using LC\u2013Q-ToF\u2013MS\/MS along with the in silico approaches for prediction of metabolites and their toxicity","volume":"38","author":"Chaganti","year":"2024","journal-title":"Biomed Chromatogr"},{"issue":"22","key":"10.1016\/j.dmd.2025.100161_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.8915","article-title":"Identification and characterization of novel metabolites of nintedanib by ultra-performance liquid chromatography\/quadrupole time-of-flight tandem mass spectrometry with in silico toxicological assessment","volume":"34","author":"Tiwari","year":"2020","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"11","key":"10.1016\/j.dmd.2025.100161_bib12","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/jms.3640","article-title":"Rapid structural characterization of in vivo and in vitro metabolites of tinoridine using UHPLC\u2013QTOF\u2013MS\/MS and in silico toxicological screening of its metabolites","volume":"50","author":"Kalariya","year":"2015","journal-title":"J Mass Spectrom"},{"issue":"3","key":"10.1016\/j.dmd.2025.100161_bib13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jpba.2009.05.009","article-title":"In vitro and in vivo investigation of metabolic fate of rifampicin using an optimized sample preparation approach and modern tools of liquid chromatography\u2013mass spectrometry","volume":"50","author":"Prasad","year":"2009","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"10.1016\/j.dmd.2025.100161_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd4581","article-title":"Predicting drug metabolism: experiment and\/or computation?","volume":"14","author":"Kirchmair","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dmd.2025.100161_bib15","article-title":"Comparing the performance and coverage of selected in silico (liver) metabolism tools relative to reported studies in the literature to inform analogue selection in read-across: a case study","volume":"21","author":"Boyce","year":"2022","journal-title":"Comput Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100161_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41021-020-00163-1","article-title":"An assessment of mutagenicity of chemical substances by (quantitative) structure\u2013activity relationship","volume":"42","author":"Honma","year":"2020","journal-title":"Genes Environ"},{"issue":"1","key":"10.1016\/j.dmd.2025.100161_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41021-020-00166-y","article-title":"The importance of expert review to clarify ambiguous situations for (Q) SAR predictions under ICH M7","volume":"42","author":"Foster","year":"2020","journal-title":"Genes Environ"},{"key":"10.1016\/j.dmd.2025.100161_bib18","series-title":"Liquid Chromatography-Mass Spectrometry","author":"Niessen","year":"2006"},{"issue":"23","key":"10.1016\/j.dmd.2025.100161_bib19","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1039\/C6AN01753C","article-title":"Strategies for large-scale targeted metabolomics quantification by liquid chromatography-mass spectrometry","volume":"141","author":"Zhou","year":"2016","journal-title":"Analyst"},{"issue":"10","key":"10.1016\/j.dmd.2025.100161_bib20","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00277-022-04945-1","article-title":"Bosutinib-induced late-onset severe liver injury preceded by eosinophilia","volume":"101","author":"Watanabe","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dmd.2025.100161_bib21","unstructured":"Bosulif: European Public Assessment Report (EPAR), European Medicines Agency (EMA). Accessed 30 July 2025. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf. 2013"},{"issue":"10","key":"10.1016\/j.dmd.2025.100161_bib22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","article-title":"Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.dmd.2025.100161_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12185-025-03954-w","article-title":"Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia","volume":"122","author":"Abumiya","year":"2025","journal-title":"Int J Hematol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562509470X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562509470X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:14:45Z","timestamp":1761714885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562509470X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S009095562509470X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100161","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural characterization of in vivo and in vitro metabolites of bosutinib by liquid chromatography-tandem mass spectrometry, in combination with the in silico methodologies for toxicity and metabolism prediction","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100161"}}